Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Traws Pharma Inc
TRAWCurrent price
0.31 USD
-0.0098 USD (-3.06%)
Last closed
0.34 USD
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
8 851 432 USD
Yield for 12 month
-59.21 %
1Y
3Y
5Y
10Y
15Y
TRAW
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Address: 12 Penns Trail, Newtown, PA, United States, 18940
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.5 USDP/E ratio
–Dividend Yield
–Current Year
+226 000 USD
Last Year
+226 000 USD
Current Quarter
+57 000 USD
Last Quarter
+56 000 USD
Current Year
+210 000 USD
Last Year
+212 000 USD
Current Quarter
+53 000 USD
Last Quarter
+52 000 USD
Key Figures TRAW
1 year
3 years
5 years
10 years
EBITDA
-20 630 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-52.51 %
PEG Ratio
–
Return On Equity TTM
-1096.52 %
Wall Street Target Price
6.5 USD
Revenue TTM
226 000 USD
Book Value
-4.17 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-5.95 USD
Diluted Eps TTM
-5.95 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics TRAW
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TRAW
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:15
Payout Ratio
–
Last Split Date
21.05.2021
Dividend Date
–
Stock Valuation TRAW
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1.2538
Price Sales TTM
39.1656
Enterprise Value EBITDA
0.3293
Price Book MRQ
1.6745
Financials TRAW
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TRAW
For 52 weeks
0.33 USD
1.1 USD
50 Day MA
0.38 USD
Shares Short Prior Month
22 753
200 Day MA
0.62 USD
Short Ratio
0.36
Shares Short
23 364
Short Percent
0.09 %
BeatStart